GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » La Jolla Pharmaceutical Co (NAS:LJPC) » Definitions » Days Sales Outstanding

La Jolla Pharmaceutical Co (La Jolla Pharmaceutical Co) Days Sales Outstanding : 50.44 (As of Jun. 2022)


View and export this data going back to 1994. Start your Free Trial

What is La Jolla Pharmaceutical Co Days Sales Outstanding?

La Jolla Pharmaceutical Co's average Accounts Receivable for the three months ended in Jun. 2022 was $5.83 Mil. La Jolla Pharmaceutical Co's Revenue for the three months ended in Jun. 2022 was $10.54 Mil. Hence, La Jolla Pharmaceutical Co's Days Sales Outstanding for the three months ended in Jun. 2022 was 50.44.

The historical rank and industry rank for La Jolla Pharmaceutical Co's Days Sales Outstanding or its related term are showing as below:

LJPC' s Days Sales Outstanding Range Over the Past 10 Years
Min: 34.36   Med: 41.42   Max: 59.12
Current: 59.12

During the past 13 years, La Jolla Pharmaceutical Co's highest Days Sales Outstanding was 59.12. The lowest was 34.36. And the median was 41.42.

LJPC's Days Sales Outstanding is not ranked
in the Biotechnology industry.
Industry Median: 71.97 vs LJPC: 59.12

La Jolla Pharmaceutical Co's Days Sales Outstanding increased from Jun. 2021 (36.22) to Jun. 2022 (50.44).


La Jolla Pharmaceutical Co Days Sales Outstanding Historical Data

The historical data trend for La Jolla Pharmaceutical Co's Days Sales Outstanding can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

La Jolla Pharmaceutical Co Days Sales Outstanding Chart

La Jolla Pharmaceutical Co Annual Data
Trend Dec12 Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21
Days Sales Outstanding
Get a 7-Day Free Trial Premium Member Only Premium Member Only - 50.13 34.36 48.02 34.81

La Jolla Pharmaceutical Co Quarterly Data
Sep17 Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22
Days Sales Outstanding Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 36.22 59.59 65.03 62.75 50.44

Competitive Comparison of La Jolla Pharmaceutical Co's Days Sales Outstanding

For the Biotechnology subindustry, La Jolla Pharmaceutical Co's Days Sales Outstanding, along with its competitors' market caps and Days Sales Outstanding data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


La Jolla Pharmaceutical Co's Days Sales Outstanding Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, La Jolla Pharmaceutical Co's Days Sales Outstanding distribution charts can be found below:

* The bar in red indicates where La Jolla Pharmaceutical Co's Days Sales Outstanding falls into.



La Jolla Pharmaceutical Co Days Sales Outstanding Calculation

Days Sales Outstanding measures the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

Accounts Receivable can be measured by Days Sales Outstanding.

La Jolla Pharmaceutical Co's Days Sales Outstanding for the fiscal year that ended in Dec. 2021 is calculated as

Days Sales Outstanding (A: Dec. 2021 )
=Average Accounts Receivable /Revenue*Days in Period
=( (Accounts Receivable (A: Dec. 2020 ) + Accounts Receivable (A: Dec. 2021 )) / count ) / Revenue (A: Dec. 2021 )*Days in Period
=( (5.834 + 8.61) / 2 ) / 75.72*365
=7.222 / 75.72*365
=34.81

La Jolla Pharmaceutical Co's Days Sales Outstanding for the quarter that ended in Jun. 2022 is calculated as:

Days Sales Outstanding (Q: Jun. 2022 )
=Average Accounts Receivable /Revenue*Days in Period
=( (Accounts Receivable (A: Mar. 2022 ) + Accounts Receivable (A: Jun. 2022 )) / count ) / Revenue (A: Jun. 2022 )*Days in Period
=( (5.729 + 5.927) / 2 ) / 10.543*365 / 4
=5.828 / 10.543*365 / 4
=50.44

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


La Jolla Pharmaceutical Co  (NAS:LJPC) Days Sales Outstanding Explanation

For retailers, when we compare Days Sales Outstanding, it is important to compare the same period in the previous years.


La Jolla Pharmaceutical Co Days Sales Outstanding Related Terms

Thank you for viewing the detailed overview of La Jolla Pharmaceutical Co's Days Sales Outstanding provided by GuruFocus.com. Please click on the following links to see related term pages.


La Jolla Pharmaceutical Co (La Jolla Pharmaceutical Co) Business Description

Traded in Other Exchanges
N/A
Address
201 Jones Road, Suite 400, Waltham, MA, USA, 02451
La Jolla Pharmaceutical Co is a biopharmaceutical company. The company's main activity is the discovery, development, and commercialization of innovative therapies that improve patients' life-threatening conditions. The company's portfolio consists of an angiotensin II formulation, which regulates blood pressure; a formulation of hepcidin, an endogenous peptide hormone that regulates iron metabolism; and an antibiotic approved by the U.S. Food and Drug Administration.
Executives
Larry G. Edwards director, officer: Chief Executive Officer C/O TETRAPHASE PHARMACEUTICALS, INC., 480 ARSENAL STREET, SUITE 110, WATERTOWN MA 02472
David A Ramsay director HALOZYME THERAPEUTICS, INC., 11588 SORRENTO VALLEY ROAD, #17, SAN DIEGO CA 92121
Craig A Johnson director C/O PURE BIOSCIENCE, 1725 GILLESPIE WAY, EL CAJON CA 92020
Michael S Hearne officer: Chief Financial Officer 4747 EXECUTIVE DRIVE SUITE 210 SAN DIEGO CA 92121
Robert Rosen director C/O HERON THERAPEUTICS, INC, 4242 CAMPUS POINT COURT, SUITE 200, SAN DIEGO CA 92121
Kevin C Tang director, 10 percent owner 4747 EXECUTIVE DRIVE, SUITE 210, SAN DIEGO CA 92121
Laura L. Johnson director C/O LA JOLLA PHARMACEUTICAL COMPANY, LA JOLLA VILLAGE DRIVE, SUITE 1070, SAN DIEGO CA 92122
Darryl Wellinghoff officer: Chief Commercial Officer 4550 TOWNE CENTRE COURT SAN DIEGO CA 92121
Lakhmir S Chawla officer: Chief Medical Officer 1960 KIRBY ROAD, MCLEAN VA 22101
Jennifer Carver officer: Sr. Vice President, Operations 725 NEWPORT STREET, DENVER CO 80220
James Rolke officer: Chief Scientific Officer 10182 TELESIS COURT, 6TH FLOOR, SAN DIEGO CA 92121
Perceptive Life Sciences Master Fund Ltd 10 percent owner C/O PERCEPTIVE ADVISORS LLC, 51 ASTOR PLACE, 10TH FLOOR, NEW YORK NY 10003
Joseph Edelman 10 percent owner C/O PERCEPTIVE ADVISORS LLC, 51 ASTOR PLACE, 10TH FLOOR, NEW YORK NY 10003
Perceptive Advisors Llc 10 percent owner 51 ASTOR PLACE, 10TH FLOOR, NEW YORK NY 10003
George F Tidmarsh director, officer: President, CEO & Secretary

La Jolla Pharmaceutical Co (La Jolla Pharmaceutical Co) Headlines

From GuruFocus

La Jolla Pharmaceutical Company Announces Management Transition

By Marketwired Marketwired 11-25-2019

La Jolla Pharmaceutical Company Announces Share Repurchase Plan

By Business Wire Business Wire 11-17-2021